SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC® (NALDEMEDINE), AN OPIOID-INDUCED CONSTIPATION ...
(WorldNews Business)

AMSTERDAM & FLORENCE, Italy--(BUSINESS WIRE)--May 22, 2019-- SHIONOGI B.V., the European subsidiary of SHIONOGI & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter `Shionogi`) and L. MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A. (Headquarters: Florence, Italy; Managing Director : Giuseppe Seghi Recli, hereafter `Molteni`) announced today that Shionogi and Molteni concluded a contract for the distribution and sale of RIZMOIC ® (naldemedine) for the treatment of opioid-induced constipation (OIC) in adult patients previously treated with a laxative in the two key European markets, Italy and Poland. This press release features...